目的 总结托伐普坦治疗多囊肾病的研究热点及研究现状，为托伐普坦的临床应用与进一步研究提供参考。方法 采用计算机检索Web of Science核心合集中的Science Citation Index Expanded(SCI-E)数据库中自建库起至2023年12月31日的托伐普坦治疗多囊肾病的相关文献，采用VoSviewer 1。6。18软件及CiteSpace 6。2。R5软件对发文国家、机构、作者、高被引论文、关键词等进行文献计量学分析。结果 共纳入405篇文献，发文量总体呈逐年上升趋势。共涉及36个国家、677个机构，其中发文量最多的国家及机构分别为美国(180篇)和梅奥医学中心(68篇)。来自美国梅奥医学中心的TORRES VE的发文量最多(51篇)，总被引频次最高(3 644次)。近年来，该领域的研究重点为托伐普坦对常染色体显性多囊肾病(ADPKD)进展的作用及其作用机制;研究热点为托伐普坦对ADPKD患者肾功能及生活质量的影响，托伐普坦代谢相关研究，托伐普坦对超重患者多囊肾病的治疗作用等。结论 欧美国家在托伐普坦治疗多囊肾病的研究领域已处于领先水平，作者之间和各研究机构之间的合作较紧密。我国未来应加强国际合作，针对亚太人群开展相关研究，为进一步全面、深入研究提供了参考。
Bibliometric Analysis of Tolvaptan in the Treatment of Polycystic Kidney Disease Based on the Web of Science Core Collection
Objective To summarize the research hotspots and current status of tolvaptan in the treatment of polycystic kidney disease,and to provide a reference for the clinical application and further research of tolvaptan.Methods The literature related to tolvaptan in the treatment of polycystic kidney disease in the Science Citation Index Expanded(SCI-E)database in the Web of Science Core Collection was searched from the inception to December 31,2023.VoSviewer 1.6.18 software and CiteSpace 6.2.R5 software were used for bibliometric analysis of the countries,institutions,authors,highly cited papers,keywords,etc.Results A total of 405 articles were included,and the overall publication volume showed an increasing trend year by year.The articles was published from 677 institutions in 36 countries,the country with the largest number of studies was the United States of American(180 articles),and institutions with the largest number of studies was the Mayo Clinic(68 articles).TORRES VE from the Mayo Clinic was the leading author with the most articles(51 articles)and widely cited articles(3 644 times)in this area.In recent years,the research has focused on the effect and its mechanism of tolvaptan on disease progression in patients with autosomal dominant polycystic kidney disease(ADPKD).The research hotspots included the effect of tolvaptan on renal function and quality of life in ADPKD patients,studies on metabolism of tolvaptan,and the therapeutic effect of tolvaptan on polycystic kidney disease in overweight patients.Conclusion Researches on tolvaptan in the treatment of polycystic kidney disease in European and American countries are at the leading level,with close cooperation between authors and various research institutions.In the future,China should strengthen international cooperation and conduct relevant research on the Asia Pacific population to provide a reference for further comprehensive and in-depth research.
tolvaptanpolycystic kidney diseaseWeb of Science Core Collectionbibliometricsvisual analysis
万方数据
维普
